Matribhumi Samachar English
First Patients Expected to be Enrolled This Month Halifax, Nova Scotia–(Newsfile Corp. – June 16, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company“, “Sona“) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into …
Read More »Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
Halifax, Nova Scotia–(Newsfile Corp. – May 15, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce the successful completion of bacterial endotoxin testing (“BET”) on Sona’s uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate (“LAL”) method at a leading global provider of …
Read More »Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model
Halifax, Nova Scotia–(Newsfile Corp. – March 19, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to provide updated data confirming efficacy of its Targeted Hyperthermia Therapy (“THT”) cancer treatment in an immunotherapy resistant cancer. In this follow-up data to the previously released preliminary study …
Read More »Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Halifax, Nova Scotia–(Newsfile Corp. – February 12, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that its recently published findings from its “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” study …
Read More »